COPD360social Community Exchange

What's the purpose of the MATINEE study?

The main purpose of the MATINEE study is to test an investigational medication in adults who have more advanced COPD. The study doctors want to learn whether it can help decrease the rate of symptom “flare-ups” in these COPD patients.

Do I qualify to join the study?

You may qualify to participate in this study if you:

• Are 40 years of age or older
• Are a current or former smoker living with COPD
• Take 2 or more medications for your COPD in addition to an inhaled corticosteroid
• Have had 2 or more flareups that needed treatment OR 1 or more flare-ups of your COPD symptoms that required hospitalization in the past year

Worried about your next flare-up? COPD flare-ups can hit at any time. That's why our clinical trial is seeing if a once-a-month shot could help reduce them.

You may qualify if you:

• Have COPD
• Are 40 or older
• Smoke or used to smoke
• Have had a flare-up in the last year

Find out if you're eligible. Learn more here.

Are you interested in joining a new COPD study? Capnography-Assisted, Learned, Monitored (also known as CALM) Breathing Therapy for COPD is a breathing intervention for people with COPD that uses breathing exercises and biofeedback with the goal of reducing shortness of breath and stress and improving quality of life. The intervention is a four-week (one-hour, twice weekly) program taking place in-person at New York Presbyterian Hospital and Columbia University Irving Medical Center in New York City, New York. The breathing therapy is implemented before pulmonary rehabilitation.

Eligibility Criteria:
Main eligibility criteria include a COPD diagnosis and the ability to read and speak English.

Learn more if interested by contacting Brittany Hofferber, CALM Breathing Research Coordinator at (732) 551-4127 or via email: bth2119@cumc.columbia.edu.

Clinical Trial.GOV: https://clinicaltrials.gov/ct2/show/NCT04786184
NCCIH/NIH Grant number: NCT04786184
Contact Information:
Brittany Hofferber
CALM Breathing Research Coordinator
617 W 168th St, NY, NY 10032
Bth2119@cumc.columbia.edu
732-551-4137

This research study at the Medical University of South Carolina (MUSC) is for women with chronic obstructive pulmonary disease (COPD) and to evaluate any unmet care needs. If you are a woman with COPD, you may qualify to participate in this study.

If you are interested in participating? Please click here to learn more.

If you have any questions or would like to participate in this research study, please contact Jessica Madiraca at 856-399-1678 or madiraca@musc.edu.

Motivate others with your story!

If you have COPD and have benefited from Pulmonary Rehabilitation (PR), the COPD Foundation and Baystate Health invite you to share your experiences in this NIH-funded study to help motivate others to attend PR.

Share your story in a recorded 10-minute video call. Receive a $50 gift card for your time. To learn more, fill out this short contact form or contacts Raj Kotejoshyer, ScD, with Baystate Health at (413) 794-7909 or by email at rajashree.kotejoshyer@baystatehealth.org.

We are conducting a research study to learn more about stigma experienced by people with chronic obstructive pulmonary disease. As you may know, many people with COPD have experienced stigma and this can have a negative effect on their physical and mental health. The knowledge we gain from this research will be useful in developing and evaluating a questionnaire designed to measure COPD related stigma.

Approximately 300 people will participate in this research. We expect it to take about 20 minutes to complete the survey. If you decide to take part in the study, we’ll ask you to complete the online questionnaires.

You are eligible to take part in this study if:

• you are at least 45 years old
• you are diagnosed with or being told by your primary care provider that you have COPD, emphysema, or chronic bronchitis
• you are able to speak and read English as the first language

You are not eligible to take part in this research if:

• you are diagnosed with a mental illness, HIV/AIDS, lung cancer, or severe physical deformities.

Before beginning the questionnaire, please read the “Consent Form for a Research Project on Development and Psychometric Assessment of the COPD-Related Stigma Scale” at the top of the questionnaires, describing the purpose of this study, benefits and risks and procedures. All of your answers will be kept confidential. No one outside of the study team will be informed of your individual answers. You will receive a $10 gift card for completing this survey.

Thank you very much for your participation. If you have any questions about this study, please contact the principal investigator, Seoyoon Woo, by phone at 910-962-3843 or email at woos@uncw.edu.

The COPD Foundation is pleased to be able to share opportunities regarding research studies with COPD360social members. If you have any questions about this opportunity, please contact your physician or the link at the end of this post.

COPD patients take inhaled medicines (like ipratropium bromide and tiotropium) which help decrease mucus production and block reflexes produced by airway nerves that contribute to COPD symptoms.¹ Inhaled medicines can help patients manage their COPD symptoms, but are challenging for patients in several ways:

• Copays for COPD medications can be expensive
• Patients must remember to take their COPD medications every day as prescribed for them to work effectively
• Using the inhaler devices correctly and getting these medications into the smaller airways is difficult, particularly for people with poor lung function, i.e. people with COPD!

Over a three-year period, nearly 50% of patients with COPD will suffer at least one COPD flare-up despite taking their routine COPD inhalers¹. A COPD flare-up is when your COPD symptoms become much worse than normal, and you need to seek additional medical care. This happens when the COPD medications are overwhelmed by airway nerve activity, typically resulting from bacteria or viruses, and are unable to keep mucus low and airways open. Patients may need urgent care or may even be hospitalized, although most flare-ups can be managed with additional prescriptions, usually for steroids and/or antibiotics. However, these medications have worrisome side effects, especially with long-term use^2,3 . And COPD flare-ups worsen lung function, exercise tolerance and quality of life for weeks or even months, making it difficult for patients to recover.

The COPD Foundation is partnering with Collaboration in COPD Exacerbations (CICERO) and the European Lung Foundation(ELF) to ask patients to share their thoughts on questionnaires that have been developed to assess how COPD affects your daily life. We understand that questionnaires are sometimes long and difficult. We also want to hear your thoughts on how care can be improved.

Please visit the ELF website and share your story by taking the survey: https://europeanlung.org/en/get-involved/surveys/involving-patients-in-copd-research/

Before a medical device can be approved for use in a general population, a thorough process of research must be done. Clinical studies are one of the key steps in that process. Doctors are enrolling volunteers for a treatment in a clinical study that may have the potential to reduce COPD Flare-ups.

If you have COPD and still experience flare-ups despite your medications, you may qualify for the AIRFLOW-3 Clinical Trial. The trial is evaluating Targeted Lung Denervation, an investigational treatment which may have the potential to reduce the risk of COPD flare-ups through a one-time, non-surgical, outpatient procedure.

New COPD research can’t move forward without volunteers like you. Answer a few questions to see if you may be eligible to take part. Visit https://airflowtrial.com to complete a short survey.

Participating in clinical trials is one way to support the entire COPD population and help researchers develop treatment options at the same time. Two previous studies have shown that investigational study drug might reduce moderate-to-severe symptom flare-ups for people living with COPD. A new clinical trial is further evaluating this drug in individuals with COPD, and volunteers are needed.

To qualify, you must:

• Be 40-85 years of age.
• Be a current or former smoker living with COPD.
• Have a history of moderate-to-very-severe COPD.
• Have had three or more flare-ups of your COPD symptoms in the last year that required steroid treatment or medical attention.
• Have used multiple types of medications to treat your COPD in the past three months (this may be with one or more inhalers).
• Not have an asthma diagnosis.

New COPD research can’t move forward without volunteers like you. Answer a few questions to see if you may be eligible to take part.

Yes, see if I may qualify!

If you have any questions about the study or technical difficulty completing the Pre-screener, you can call 888-509-1308 or email patientsupport@antidote.me.

The author of this survey is a nurse and PHD student putting together her thesis. She is asking for our communities support in gathering data. The COPD Foundation is not involved in this survey

The purpose of this study is to learn if situational factors, such as social support and stress, are associated with other factors such as mood and breathing levels, and if all these factors are associated with COPD-related fatigue. It is important to participate because we hope to learn more about COPD-related fatigue to develop better treatment for fatigue in the future. We also hope to explore the lived experience of fatigue in adults with COPD during a global pandemic as compared to prior to the pandemic.

To take the survey click on the following link: https://umaryland.az1.qualtrics.com/jfe/form/SV_74cLnRJNBEdsuZo